MEDXF - Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc.
35 Nixon Road
Unit 1
Bolton, ON L7E 1K1
Canada
877 633 3987
https://www.medexus.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 100
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Kenneth d'Entremont | CEO & Director | 592k | N/A | N/A |
| Mr. Marcel Konrad | Chief Financial Officer | 405.77k | N/A | 1976 |
| Ms. Tina Byers CFA | Exec. of Investor Relations | N/A | N/A | N/A |
| Mr. Ian C. Wildgoose Brown | Gen. Counsel & Corp. Sec. | N/A | N/A | N/A |
| Mr. Bill Poncy | Sr. VP of Commercial Operations - United States | N/A | N/A | N/A |
| Mr. Brian Peters | VP of Sales & Marketing - United States | N/A | N/A | N/A |
Description
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Corporate governance
Medexus Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
